Current and Emerging Biologics for Ulcerative Colitis

566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis

(2015) Walter Reinisch et al.   GASTROENTEROLOGY

159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis

(2015) Severine Vermeire et al.   GASTROENTEROLOGY

Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166)

(2014) Emily Stenke et al.   Archives of Disease in Childhood-Education and Practice Edition

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis

(2013) Sang Hyoung Park et al.   DIGESTIVE DISEASES AND SCIENCES

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

(2013) Kang-Moon Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

(2012) David Laharie et al.   LANCET

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?

(2011) Pal Miheller et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

(2009) Klaus Bendtzen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Colectomy rate in acute severe ulcerative colitis in the infliximab era

(2008) A. Aratari et al.   DIGESTIVE AND LIVER DISEASE

The European consensus on ulcerative colitis: new horizons?

(2008) E. F Stange et al.   GUT

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS